Find Clinical Trials

Search thousands of clinical trials by condition, location, and eligibility criteria

0
Total Trials
0
Trials Recruiting
0
Conditions Covered
0
Locations Worldwide
0
Sponsors
Clinical trial guides

Browse trials by condition

View all guides

Browse by location

Showing 12 of 4281 trials
Conditions Depression, Anxiety
Phase NA
Enrollment 688
Locations 1 sites
Compensation Not reported — ask the study team
Data Updated 2026-09-27
Study Details Design, interventions, and primary outcomes

About This Study

The overall purpose of this study is to help determine how best to incorporate small amounts of human and digital support into a meditation app. The meditation app used is the Healthy Minds Program (HMP) which provides training in four pillars of well-being (Awareness, Connection, Insight, Purpose) through a combination of podcast-style didactic material and guided meditation practices.

Design

Study type: Interventional Phases: Allocation: Randomized Intervention model: Parallel Primary purpose: Treatment Masking/blinding: None

Interventions / Regimen

  • Other: Introductory Coaching Session — Participant is randomized to receive a 30-minute meditation coaching session
  • Other: Introductory Information Session — Participant is randomized to receive a 30-minute information session
  • Other: On-Demand Email Support — email support throughout the 4 week intervention period
  • Other: Microsupport — Text message microsupport throughout the 4 week intervention period

Primary Outcomes

  • Patient Health Questionnaire Anxiety and Depression Scale (PHQ-ADS) Score (baseline, week 1, week 2, week 3, week 4, 6-month follow up)
  • Anxiety Measured from Evening Daily Diary Items (Daily through the Intervention Period (up to 4 weeks))
  • Depression Measured from Evening Daily Diary Items (Daily through the Intervention Period (up to 4 weeks))
Interested in this trial?
Contact the study team directly or view the official listing
Study Information
Type: INTERVENTIONAL
Phase: NA
Status: Recruiting
Start Date: 2026-03-13
Completion: 2029-01-31
Eligibility
Age: 18 Years and older
Sex: ALL
Volunteers: true
Enrollment: 688 (ESTIMATED)
Sponsor & Investigators
Lead Sponsor: University of Wisconsin, Madison
Collaborators: National Institute of Mental Health (NIMH)
Principal Investigators:
  • Simon Goldberg, PhD (PRINCIPAL_INVESTIGATOR) - UW Madison
Contact Information
Study Contact:
Wendy Lau, PhD
608-890-2747
wendy.lau@wisc.edu
Interventions
  • Other: Introductory Coaching Session — Participant is randomized to receive a 30-minute meditation coaching session
  • Other: Introductory Information Session — Participant is randomized to receive a 30-minute information session
  • Other: On-Demand Email Support — email support throughout the 4 week intervention period
  • Other: Microsupport — Text message microsupport throughout the 4 week intervention period
Study Locations (1 sites)
Center for Healthy Minds, Madison, Wisconsin 53703 United States
Eligibility Criteria
Inclusion Criteria: * Elevated symptoms of depression and/or anxiety (PHQ-9 greater than or equal to 10, GAD-7 greater than or equal to 10) * Proficiency in English * Access to a smartphone and internet * Ability to receive text messages Exclusion Criteria: * Non-US citizen or legal resident (green card holder) * History of psychosis or mania * Suicidal ideation or thoughts of self-harm indicated by PHQ9 item 9 and BDI item 9 * Individuals who do not provide the information required for GUID generation * Previous participation * Individuals who do not have their camera turned on and remain visible on camera during the virtual introductory and coaching sessions (if applicable).
Conditions Postpartum Depression (PPD), Self-Effica...
Phase NA
Enrollment 150
Locations 1 sites
Compensation Not reported — ask the study team
Data Updated 2026-09-27
Study Details Design, interventions, and primary outcomes

About This Study

The study's objective is to conduct a Phase II randomized controlled trial examining the preliminary efficacy of the VoiceLove app compared to usual care on maternal postpartum depression in mothers with infants admitted to the Neonatal Intensive Care Unit (NICU). Primary aim: Assess the effects of VoiceLove on maternal postpartum depression, measured by the Edinburgh Postnatal Depression Scale (EPDS). The estimates from this study will be used for a future definitive Phase III trial. Secondary aim: Assess feasibility, acceptability, and patterns of communication and engagement among mothers, partners, and NICU clinicians during the NICU hospitalization, measured through app usage metrics, satisfaction surveys, and qualitative interviews. Additionally, we will evaluate effects of infant length of stay.

Design

Study type: Interventional Phases: Allocation: Randomized Intervention model: Parallel Primary purpose: Supportive Care Masking/blinding: None

Interventions / Regimen

  • Device: VoiceLove mobile phone application — Access to VoiceLove app to facilitate secure, real-time communication between family members and NICU patients.

Primary Outcomes

  • Patient Engagement with the VoiceLove App (2-weeks post randomization.)
  • Edinburgh Postnatal Depression Score (EPDS) at 2-weeks post randomization. (2-weeks post randomization.)
Interested in this trial?
Contact the study team directly or view the official listing
Study Information
Type: INTERVENTIONAL
Phase: NA
Status: Recruiting
Start Date: 2026-02-04
Completion: 2028-01
Eligibility
Age: 18 Years and older
Sex: FEMALE
Volunteers: true
Enrollment: 150 (ESTIMATED)
Sponsor & Investigators
Lead Sponsor: Vanderbilt University Medical Center
Collaborators: National Institute of Mental Health (NIMH)
Principal Investigators:
  • Sarah Osmundson (PRINCIPAL_INVESTIGATOR) - Vanderbilt University Medical Center
Contact Information
Study Contact:
Makenna Woods
615-936-2938
makenna.woods.1@vumc.org
Makenna Woods
615-936-2938
makenna.woods.1@vumc.org
Vanderbilt University Medical Center
Sarah Osmundson
Vanderbilt University Medical Center
Interventions
  • Device: VoiceLove mobile phone application — Access to VoiceLove app to facilitate secure, real-time communication between family members and NICU patients.
Study Locations (1 sites)
Vanderbilt University Medical Center, Nashville, Tennessee 37232 United States
Eligibility Criteria
Inclusion Criteria: 1. Infant: 1. Admitted to the neonatal intensive care unit (NICU) 2. Not readmitted after discharge from the NICU 3. Expected to survive at least 2 weeks 4. Expected to be admitted to the NICU for at least 2 weeks 5. Singleton gestation 2. Mother: 1. Age ≥ 18 years old 2. English speaking 3. Mother is the biological mother of the infant admitted to the NICU 4. Postpartum day 4 or less 3. Partner (NOTE: Partner enrollment is not required) 1. Mother agrees to partner's participation 2. Designated by mother as support person with infant access Exclusion Criteria 1. Infant a. Re-admission to NICU 2. Mother 1. No access to an Android or iOS smartphone 2. Unwilling to download the VoiceLove NICU app to their personal smartphone and unwilling to accept the terms and conditions of the VoiceLove app 3. No personal email address 4. Incarcerated at time of delivery or postpartum 5. Inability to obtain informed consent i. Patient's clinician refuses enrollment of the patient ii. Patient is either mentally (acute psychosis) or physically (intubated or critically ill in the ICU) unable to provide informed consent f. Unable to approach the patient (staffing, patient unavailable) g. Mother is not the intended parent (plans adoption, is a surrogate, will not have custody of the infant) 3. Partner (NOTE: Partner enrollment is not required) 1. Age \< 18 years old 2. Not English speaking 3. Inability to obtain informed consent 4. No access to an Android or iOS smartphone that is different from the mother's smartphone 5. No access to an email address that is different from the mother's email address 6. Unwilling to download the VoiceLove NICU app to their personal smartphone and unwilling to accept the terms and conditions of the VoiceLove app
Conditions Stress, Psychological, Depression and/or...
Phase NA
Enrollment 50
Locations 1 sites
Compensation Not reported — ask the study team
Data Updated 2026-09-27
Study Details Design, interventions, and primary outcomes

About This Study

The goal of this clinical trial is to learn if an adapted version of Self-Help Plus (SH+), a stress management program developed by the World Health Organization, can reduce stress and improve well-being in international students at a U.S. university. The main questions it aims to answer are: Does SH+ reduce perceived stress, anxiety, and depressive symptoms in international students? Does SH+ improve feelings of social support, self-efficacy, and adjustment in a new cultural environment? Participants will: Attend a two-day in-person workshop that includes animated videos, interactive activities, and group discussions. Complete three surveys (before the workshop, right after, and six weeks later) about stress, mood, and well-being. Optionally, take part in a short interview to share feedback about their experience.

Design

Study type: Interventional Phases: Allocation: Intervention model: Single Group Primary purpose: Supportive Care Masking/blinding: None

Interventions / Regimen

  • Behavioral: Digitized SH+ — Digitized SH+ is a group-based, stress management program (adapted from the original Self-Help Plus intervention developed by the World Health Organization), that utilizes animated videos and group discussions to teach participants skills such as Grounding, Unhooking (from difficult thoughts), Being Kind (to self and others), Identifying Values, and Making Room for Difficult Thoughts and Feelings.

Primary Outcomes

  • Perceived Stress Scale (PSS-10) (Change from baseline to 6-week follow-up)
  • Patient Health Questionnaire (PHQ-9) (Change from baseline to 6-week follow-up)
  • General Anxiety Disorder (GAD-7) (Change from baseline to 6-week follow-up)
Interested in this trial?
Contact the study team directly or view the official listing
Study Information
Type: INTERVENTIONAL
Phase: NA
Status: Recruiting
Start Date: 2025-10-07
Completion: 2026-01
Eligibility
Age: 18 Years and older
Sex: ALL
Volunteers: true
Enrollment: 50 (ESTIMATED)
Sponsor & Investigators
Lead Sponsor: The New School
Principal Investigators:
  • Adam D Brown, PhD (PRINCIPAL_INVESTIGATOR) - The New School, Center for Global Mental Health
Contact Information
Study Contact:
Josheka S Chauhan, MA
347-307-2179
chauj265@newschool.edu
Josheka Chauhan
3473072179
chauj265@newschool.edu
The New School
Adam D. Brown, PhD
The New School
Interventions
  • Behavioral: Digitized SH+ — Digitized SH+ is a group-based, stress management program (adapted from the original Self-Help Plus intervention developed by the World Health Organization), that utilizes animated videos and group discussions to teach participants skills such as Grounding, Unhooking (from difficult thoughts), Being Kind (to self and others), Identifying Values, and Making Room for Difficult Thoughts and Feelings.
Study Locations (1 sites)
The New School, Brooklyn, New York 10011 United States
Eligibility Criteria
Inclusion Criteria: * Enrolled as an international student at The New School * Age 18 years or older * Willing to provide informed consent and complete study assessments * Score of ≥3 on the PHQ-4, indicating at least mild distress * Sufficient English proficiency to comprehend intervention materials Exclusion Criteria: * Severe psychiatric conditions requiring immediate intervention (e.g., active psychosis, severe mood disorders) * Visual, hearing, or neurocognitive impairments that prevent engagement with the intervention * Having an advanced degree in psychology or mental health-related fields (to prevent prior knowledge bias) * Score of 2 or higher on PHQ-4 Item 3 or Item 4 (frequent thoughts of self-harm or severe distress)
Conditions Triple-Negative Breast Cancer (TNBC)
Phase PHASE1, PHASE2
Enrollment 42
Locations 1 sites
Compensation Not reported — ask the study team
Data Updated 2026-09-27
Study Details Design, interventions, and primary outcomes

About This Study

This Phase Ib/IIa study is evaluating the safety, tolerability, pharmacokinetics, and preliminary efficacy of MR001 in patients with advanced triple-negative breast cancer (TNBC) who have progressed after prior therapy.

Design

Study type: Interventional Phases: Phase1, Phase2 Allocation: Non Randomized Intervention model: Sequential Primary purpose: Treatment Masking/blinding: None

Interventions / Regimen

  • Drug: MR001 Bispecific Antibody for Injection — Intravenous infusion

Primary Outcomes

  • Number of participants who experience one or more dose-limiting toxicities (DLTs) (Approximately 6 months)
  • Maximum Tolerated Dose (MTD) of MR001 (Approximately 6 months)
  • Incidence of Adverse Events (AEs) as Assessed by CTCAE v5.0 (Approximately 2 years)
Interested in this trial?
Contact the study team directly or view the official listing
Study Information
Type: INTERVENTIONAL
Phase: PHASE1, PHASE2
Status: Recruiting
Start Date: 2026-01-29
Completion: 2028-09-01
Eligibility
Age: 18 Years and older
Sex: ALL
Volunteers: false
Enrollment: 42 (ESTIMATED)
Sponsor & Investigators
Lead Sponsor: Shenzhen Majory Biotechnology Co., Ltd.
Principal Investigators:
  • Binghe Xu (PRINCIPAL_INVESTIGATOR) - Cancer Institute and Hospital, Chinese Academy of Medical Sciences
Contact Information
Study Contact:
Qingshan Xue
+86 13332895357
xueqs@majory.com.cn
Binghe Xu
+86-10-87788826
xubinghe@medmail.com.cn
Cancer Hospital Chinese Academy of Medical Sciences
Interventions
  • Drug: MR001 Bispecific Antibody for Injection — Intravenous infusion
Study Locations (1 sites)
Cancer Hospital Chinese Academy of Medical Sciences, Beijing, China
Eligibility Criteria
Inclusion Criteria: * Patients with histologically or cytologically confirmed triple-negative breast cancer (TNBC). * Subjects with locally recurrent or metastatic advanced TNBC who have progressed after first-line or later-line therapy. * Presence of at least one measurable lesion according to RECIST V1.1 criteria. * ECOG Performance Status 0 or 1. * Life expectancy \>3 months. * Adequate organ and hematopoietic function based on the laboratory tests. * Voluntarily sign the informed consent form. Exclusion Criteria: * History of severe allergy or hypersensitivity to the investigational product or its excipients or drugs of similar chemical class (e.g., monoclonal antibodies), or contraindications to the investigational product. * Requirement for systemic immunosuppressive therapy within 14 days prior to the first dose of study drug or during the study. * Major surgery (excluding puncture biopsy) within 4 weeks prior to the first dose of study drug, or anticipated need for major surgery during this study. * Uncontrolled active brain metastases or leptomeningeal metastasis. * History of autoimmune disease requiring treatment with corticosteroids or immunosuppressive drugs. * Women in the period of preconception, pregnancy, or lactation. * Any other circumstances which the investigator considers may increase risks to subjects or interfere with the results of the trial.
Conditions Postpartum Anxiety, Postpartum Depressio...
Phase NA
Enrollment 160
Locations 1 sites
Compensation Not reported — ask the study team
Data Updated 2026-09-27
Study Details Design, interventions, and primary outcomes

About This Study

This study tests whether a nurse-led "4-step narrative nursing" program can reduce anxiety and improve breastfeeding confidence in mothers who are having a planned or non-emergency cesarean section. What is the problem? About 30-40% of Chinese cesarean mothers feel high anxiety after surgery, and 1 in 5 is at risk for postpartum depression. Low confidence in breastfeeding is also common. What will we do? We will randomly assign 160 mothers (1:1) to either: Usual care - standard education and ward care, or Usual care plus narrative nursing - four short (10-20 min) conversations with a trained nurse: Before surgery - help the mother talk about her fears. 24-48 h after surgery - encourage her to "name" pain or worries and separate them from herself. Before discharge - guide her to find positive moments and build a "strong-mom" story. Two weeks later by phone - strengthen the new story and review feeding success. What will we measure? Main result: anxiety score at 48 h (STAI scale). Other results: depression risk, breastfeeding confidence, pain, and feeding rates up to 3 months. Possible benefits: Lower anxiety, better mood, higher breastfeeding rates. No drugs or extra procedures are involved, only talking. Risks: Minimal; some mothers may feel emotional during conversations, but nurses can pause or refer to counselling if needed.

Design

Study type: Interventional Phases: Allocation: Randomized Intervention model: Parallel Primary purpose: Supportive Care Masking/blinding: Single

Interventions / Regimen

  • Behavioral: 4-step narrative nursing program — Four nurse-led storytelling sessions (pre-operative externalization, post-operative deconstruction, pre-discharge reconstruction, and 2-week meaning-reconstruction phone call) aimed at reducing anxiety and increasing breastfeeding self-efficacy.

Primary Outcomes

  • Postpartum anxiety at 48 hours (48 hours post-surgery)
Interested in this trial?
Contact the study team directly or view the official listing
Study Information
Type: INTERVENTIONAL
Phase: NA
Status: Recruiting
Start Date: 2025-10-01
Completion: 2026-09-25
Eligibility
Age: 18 Years and older
Sex: FEMALE
Volunteers: true
Enrollment: 160 (ESTIMATED)
Sponsor & Investigators
Lead Sponsor: Xi Huang
Collaborators: Xiamen University, Yilong People's Hospital
Contact Information
Study Contact:
X i Huang
+86-156-8090-6987
24520241154909@stu.xmu.edu.cn
Yinchun Tan
+86-152-8329-4749
2027687568@qq.com
Yinchun Tan
+86-152-8329-4749
2027687568@qq.com
Yilong County Maternal and Child Health Hospital
Interventions
  • Behavioral: 4-step narrative nursing program — Four nurse-led storytelling sessions (pre-operative externalization, post-operative deconstruction, pre-discharge reconstruction, and 2-week meaning-reconstruction phone call) aimed at reducing anxiety and increasing breastfeeding self-efficacy.
Study Locations (1 sites)
Yilong County Maternal and Child Health Hospital, Nanchong, Sichuan 637600 China
Eligibility Criteria
Inclusion Criteria: 1. Women aged 18-50 years 2. Scheduled for elective or non-emergency cesarean section at ≥37 weeks 3. Able to communicate in Mandarin and provide written informed consent 4. Expected hospital stay ≥24 h 5. Singleton pregnancy with stable maternal and neonatal condition allowing routine mother-baby contact Exclusion Criteria: 1. Severe psychiatric disorders (schizophrenia, bipolar disorder, active suicidal ideation) 2. Maternal or neonatal need for ICU/NICU admission 3. Emergency cesarean section preventing baseline assessment 4. Communication or cognitive impairment precluding interview
Conditions Caregiver Stress, Social Isolation in Ol...
Phase NA
Enrollment 180
Locations 1 sites
Compensation Not reported — ask the study team
Data Updated 2026-09-27
Study Details Design, interventions, and primary outcomes

About This Study

The goal of this study is to examine the effectiveness of VR-based respite in improving cognitive function, mental health, and quality of life in caregivers and homebound older adults compared to a control group using videos and a usual care group. Participants are randomly assigned to one of three groups: VR intervention, video control, or usual care. The VR group receives immersive VR sessions using the SilVR Adventures platform. The video group receives non-immersive video sessions with similar content. The usual care group receives no additional intervention. Assessments are conducted at baseline, immediate post-intervention, and 3 months post-intervention to measure changes in depression, anxiety, loneliness, quality of life, and other outcomes. The intervention dosage will be 4 weeks (1 sessions/week; 30 min/session). Secondarily, the study explores differences in effectiveness between caregivers and homebound older adults, and potential moderators or mediators such as baseline health status, technological literacy, and social support.

Design

Study type: Interventional Phases: Allocation: Randomized Intervention model: Parallel Primary purpose: Health Services Research Masking/blinding: None

Interventions / Regimen

  • Device: VR-based Respite — Caregivers and homebound older adults will receive 4 weeks of VR-based respite sessions. 4 weeks (1 session/week; 30 min/session) of immersive VR sessions using SilVR Adventures platform. Sessions include virtual travel destinations (e.g., cities, natural wonders) and social activities (e.g., group tours). Facilitated by trained research staff, with 5-10 minutes viewing and 20 minutes reflection/discussion.
  • Device: Video-based Respite — Caregivers and homebound older adults will receive 4 weeks of video-based respite sessions. 4 weeks (1 session/week; 30 min/session) of non-immersive video sessions with content similar to VR themes (e.g., landscapes, cultural events). Facilitated by trained research staff, with post-video discussion. EEG data collected during viewing to assess emotional states.

Primary Outcomes

  • Change from baseline in depression and anxiety on PHQ-4 after intervention (Baseline, Immediate after intervention, and 3 months after intervention)
  • Change from baseline in quality of life on EQ-5D-5L after intervention (Baseline, Immediate after intervention, and 3 months after intervention)
  • Change from baseline in loneliness on UCLA Loneliness Scale after intervention (Baseline, Immediate after intervention, and 3 months after intervention)
  • Change from baseline in subjective happiness on Subjective Happiness Scale after intervention (Baseline, Immediate after intervention, and 3 months after intervention)
Interested in this trial?
Contact the study team directly or view the official listing
Study Information
Type: INTERVENTIONAL
Phase: NA
Status: Recruiting
Start Date: 2025-09-01
Completion: 2027-08-28
Eligibility
Age: 18 Years and older
Sex: ALL
Volunteers: false
Enrollment: 180 (ESTIMATED)
Sponsor & Investigators
Lead Sponsor: Hong Kong University
Contact Information
Study Contact:
Dongling Linda Wang, PhD
852-39102278
ldlw@hku.hk
Linda Wang
852-39102278
ldlw@hku.hk
Sau Po Centre on Ageing, HKU
Dongling Linda Wang, PhD
Sau Po Centre on Ageing, HKU
Interventions
  • Device: VR-based Respite — Caregivers and homebound older adults will receive 4 weeks of VR-based respite sessions. 4 weeks (1 session/week; 30 min/session) of immersive VR sessions using SilVR Adventures platform. Sessions include virtual travel destinations (e.g., cities, natural wonders) and social activities (e.g., group tours). Facilitated by trained research staff, with 5-10 minutes viewing and 20 minutes reflection/discussion.
  • Device: Video-based Respite — Caregivers and homebound older adults will receive 4 weeks of video-based respite sessions. 4 weeks (1 session/week; 30 min/session) of non-immersive video sessions with content similar to VR themes (e.g., landscapes, cultural events). Facilitated by trained research staff, with post-video discussion. EEG data collected during viewing to assess emotional states.
Study Locations (1 sites)
Sau Po Centre on Ageing, HKU, Hong Kong, 香港島 Hong Kong
Eligibility Criteria
Caregivers (CGs) Inclusion Criteria: * Aged 18 or above * Provide care to at least one homebound older adult (aged 60 or above) * Provide no less than 6 hours of caregiving per week * Able to communicate in either Cantonese, Mandarin or English * Willing to participate for the entire duration * Able to tolerate VR headset for at least 5 minutes (no severe motion sickness/epilepsy) Exclusion Criteria: * History of severe psychiatric disorders (e.g., schizophrenia, bipolar) * Severe cognitive impairment (MMSE \<10) * Major neurological diseases (e.g., recent stroke, severe Parkinson's) * Uncorrectable visual/hearing impairments affecting VR/video * Unable to tolerate VR due to motion sickness or discomfort * Care recipient receiving long-term care service that conflicts with study Care Recipients (CRs) Inclusion Criteria: * Aged 60 or above * Homebound (unable to leave home without assistance) * Stable medical condition * Willing to participate for the entire duration * Able to tolerate VR headset for at least 5 minutes (no VR contraindications) * Able to understand and provide informed consent Exclusion Criteria: Same as CGs, plus MMSE \<10
Conditions Breast Cancer
Phase PHASE3
Enrollment 100
Locations 40 sites
Compensation Not reported — ask the study team
Data Updated 2026-09-27
Study Details Design, interventions, and primary outcomes

About This Study

A study to assess the efficacy and safety of Dato-DXd in the pre-chemotherapy setting for patients with metastatic HR-positive, HER2 IHC 0 breast cancer.

Design

Study type: Interventional Phases: Phase3 Allocation: Intervention model: Single Group Primary purpose: Treatment Masking/blinding: None

Interventions / Regimen

  • Drug: Dato-DXd — All participants will receive Dato-DXd (6 mg/kg IV on Day 1, Q3W; up to a maximum of 540 mg Q3W for participants ≥ 90 kg) until investigator-defined disease progression according to RECIST 1.1 or until unacceptable toxicity, withdrawal of consent, or another criterion for discontinuation is met. Continued treatment with the same study drug post-progression may be allowed, based on prior discussion with sponsor/sponsor representative/study physician on a case-by-case basis following written investigator's confirmation of continuing clinical benefit to the patient post progression. The study is anticipated to enrol for an 18-month period, and DCO is expected to occur approximately 6 months after the last participant has been dosed.

Primary Outcomes

  • Progression Free Survival (PFS) per RECIST 1.1 as assessed by the investigator (From date of first dose of study intervention until disease progression per RECIST 1.1 or death from any cause, whichever occurs first, assessed up to approximately 24 months)
Interested in this trial?
Contact the study team directly or view the official listing
Study Information
Type: INTERVENTIONAL
Phase: PHASE3
Status: Recruiting
Start Date: 2025-10-30
Completion: 2028-02-02
Eligibility
Age: 18 Years and older
Sex: ALL
Volunteers: false
Enrollment: 100 (ESTIMATED)
Sponsor & Investigators
Lead Sponsor: AstraZeneca
Collaborators: Daiichi Sankyo
Contact Information
Study Contact:
AstraZeneca Clinical Study Information Center
1-877-240-9479
information.center@astrazeneca.com
Interventions
  • Drug: Dato-DXd — All participants will receive Dato-DXd (6 mg/kg IV on Day 1, Q3W; up to a maximum of 540 mg Q3W for participants ≥ 90 kg) until investigator-defined disease progression according to RECIST 1.1 or until unacceptable toxicity, withdrawal of consent, or another criterion for discontinuation is met. Continued treatment with the same study drug post-progression may be allowed, based on prior discussion with sponsor/sponsor representative/study physician on a case-by-case basis following written investigator's confirmation of continuing clinical benefit to the patient post progression. The study is anticipated to enrol for an 18-month period, and DCO is expected to occur approximately 6 months after the last participant has been dosed.
Study Locations (40 sites)
Research Site, Largo, Florida 33770 United States
Research Site, Fort Wayne, Indiana 46825 United States
Research Site, Omaha, Nebraska 68130 United States
Research Site, New York, New York 10021 United States
Research Site, Houston, Texas 77024 United States
Research Site, Puyallup, Washington 98373 United States
Research Site, Beijing, 100021 China
Research Site, Changsha, 410013 China
Research Site, Guangzhou, 510060 China
Research Site, Linyi, 276001 China
Eligibility Criteria
Inclusion Criteria: 1. Participant must be ≥ 18 years (and above legal age) at the time of screening. 2. Inoperable or metastatic HR-positive, HER2 IHC 0 breast cancer (per ASCO/CAP guidelines, on local laboratory results); ie, is documented as HR-positive (either ER and/or PgR positive \[ER or PgR ≥ 1%\]) and HER2 IHC 0 (defined as including HER2 null with no staining or incomplete and faint/barely perceptible membrane staining in ≤ 10% of tumour cells) based on a fresh, or recent tissue sample obtained no more than 6 weeks prior to or during the screening period. 3. Progressed on and not suitable for further endocrine therapy per investigator assessment. 4. ECOG performance status of 0 or 1, with no deterioration over the previous 2 weeks prior to the first dose of study intervention. 5. Minimum life expectancy of 12 weeks at screening. 6. Provision of acceptable tumour sample (newly acquired tumour biopsy at baseline or a tumour biopsy sample collected within 6 weeks prior to screening) as defined in the Laboratory Manual 7. Participants must have measurable disease as per RECIST 1.1 or evaluable disease. Lesions that will be subject to mandatory biopsy before, during, and after the dosing cannot be considered as TLs as per RECIST requirements. 8. Adequate bone marrow reserve and organ function within 7 days before the first dose of study intervention. 1. Haemoglobin ≥ 9.0 g/dL (red blood cell/plasma transfusion is not allowed within 1 week prior to screening assessment). 2. Absolute neutrophil count ≥ 1.5×109/L (granulocyte colony stimulating factor administration is not allowed within 1 week prior to screening assessment). 3. Platelet count ≥ 100×109/L (platelet transfusion is not allowed within 1 week prior to screening assessment). 4. Serum albumin ≥ 2.5 g/dL. 5. TBL ≤ 1.5 × ULN or ≤ 3 × ULN in the presence of documented Gilbert's syndrome (unconjugated hyperbilirubinaemia). 6. Except in the setting of HBV, ALT and AST ≤ 2.5 × ULN; for participants with hepatic metastases, ALT and AST ≤ 5 × ULN. See Exclusion Criterion 8 for requirements in the setting of HBV. 7. Calculated CrCL ≥ 30 mL/min as determined by Cockcroft Gault (using actual body weight). 9. Male and/or female assigned at birth, inclusive of all gender identities. 10. Contraceptive use by participants or participant partners should be consistent with local regulations regarding the methods of contraception for those participating in clinical studies; (a) Male participants: (i) Use of a condom plus an additional contraceptive method, or avoid intercourse throughout the duration of treatment and for at least 4 months after the last dose of Dato-DXd, in addition to the female partner using a highly effective contraceptive method. (ii) Starting at the time of first dose of Dato-DXd, male participants must not freeze or donate sperm at any time during this study and for at least 4 months after the last dose of Dato-DXd. Preservation of sperm should be considered prior to the first dose of study intervention. (b) Female participants:Female participants not of child-bearing potential (ii) Female participants receiving HRT and whose menopausal status is in doubt will be required to use one of the contraception methods outlined for WOCBP if they wish to continue using HRT during the study. Otherwise, HRT must be discontinued to allow confirmation of post-menopausal status prior to study enrolment; (iii) WOCBP must use one highly effective form of contraception or avoid intercourse throughout the duration of treatment and for at least 7 months after the last dose of Dato-DXd. All WOCBP must have a negative serum pregnancy test documented during screening. (iv) Starting at the time of first dose of Dato-DXd, female participants must not donate, or retrieve for their own use, ova at any time during this study and for at least 7 months after the last dose of Dato-DXd. Preservation of ova should be considered prior to the first dose of study intervention. 11. Capable of giving signed informed consent, which includes compliance with the requirements and restrictions listed in the ICF and in this CSP. 12. All races, genders, and ethnic groups are eligible for this study. Exclusion Criteria: 1. As judged by the investigator, any evidence of diseases (such as severe or uncontrolled systemic diseases, including active bleeding diseases and ongoing or active infection), history of allogenic organ transplant, and/or substance abuse which, in the investigator's opinion, makes it undesirable for the participant to participate in the study or that would jeopardise compliance with the protocol. 2. History of another primary malignancy except for malignancy treated with curative intent with no known active disease within 3 years before the first dose of study intervention and of low potential risk for recurrence. Exceptions include adequately resected non melanoma skin cancer (basal cell carcinoma of the skin or squamous cell carcinoma of the skin) and curatively treated in situ disease. 3. Persistent toxicities caused by previous anticancer therapy, excluding alopecia, not yet improved to Grade ≤ 1 or baseline. Note: participants may be enrolled with some chronic, stable Grade 2 toxicities (defined as no worsening to Grade \> 2 for at least 3 months prior to the first dose of study intervention and managed with SoC treatment) which the investigator deems related to previous anticancer therapy): 1. Chemotherapy-induced neuropathy 2. Fatigue 3. Residual toxicities from prior immunotherapy treatment: Grade 1 or Grade 2 endocrinopathies, which may include but are not limited to hypothyroidism/hyperthyroidism, Type I diabetes, hyperglycaemia, adrenal insufficiency, or adrenalitis; and skin hypopigmentation (vitiligo) Participants with irreversible toxicity that is not reasonably expected to be exacerbated by study intervention in the opinion of the investigator may be included (eg, hearing loss). 4. Spinal cord compression or brain metastases (unless asymptomatic, stable, and not requiring treatment with corticosteroids or anticonvulsants for at least 2 weeks prior to the first dose of study intervention). Participants with treated brain metastases that are no longer symptomatic and who require no treatment with corticosteroids or anticonvulsants must have recovered from the acute toxic effect of radiotherapy (eg, dizziness and signs of increased intracranial pressure). A minimum of 2 weeks must have elapsed between the end of brain radiotherapy and the first dose of study intervention. A minimum of 3 days must have elapsed between the end of corticosteroid therapy for CNS metastatic disease and the first dose of study intervention. 5. Leptomeningeal carcinomatosis or metastasis. 6. Has significant third-space fluid retention (eg, ascites or pleural effusion) and is not amenable for required repeated drainage. 7. Clinically significant corneal disease. 8. Has active or uncontrolled hepatitis B or C virus infection. Participants are eligible if they: 1. Have been curatively treated for HCV infection as demonstrated clinically and by viral serologies 2. Have received HBV vaccination with only anti-HBs positivity and no clinical signs of hepatitis 3. Are HBsAg- and anti-HBc+ (ie, those who have cleared HBV after infection) and meet conditions i-iii of criterion 'd' below: 4. Are HBsAg+ with chronic HBV infection (lasting 6 months or longer) and meet conditions i-iii below: (i) HBV DNA viral load \< 2000 IU/mL (ii) Have normal transaminase values or, if liver metastases are present, abnormal transaminases, with a result of AST/ALT \< 3 × ULN, which are not attributable to HBV infection (iii) Start or maintain antiviral treatment if clinically indicated as per the investigator 9. Known HIV infection that is not well controlled. All of the following criteria are required to define an HIV infection that is well controlled: undetectable viral RNA
Conditions HER2-negative Breast Cancer, Hormone Rec...
Phase NA
Enrollment 82
Locations 8 sites
Compensation Not reported — ask the study team
Data Updated 2026-09-27
Study Details Design, interventions, and primary outcomes

About This Study

The goal of this clinical trial is to learn if the TheraBionic P1 device given to patients with advanced or metastatic HR positive, HER2 negative breast cancer who have progressed on standard of care options can affect patients survival. The main questions it aims to answer are: * will the TheraBionic P1 device affect progression free and overall survival in advanced or metastatic HR positive, HER2 negative breast cancer * the long term safety and tolerability of the TheraBionic P1 device * assessment of how the disease responded to the TheraBionic P1 device

Design

Study type: Interventional Phases: Allocation: Intervention model: Single Group Primary purpose: Treatment Masking/blinding: None

Interventions / Regimen

  • Device: TheraBionic P1 — Amplitude-modulated electromagnetic fields will be self-administered and given continuously to patients in three 60-minute treatments per day, administered in the morning, middle of the day, and in the evening

Primary Outcomes

  • Progression Free Survival (PFS) (From start of treatment to 5 years after treatment discontinuation or death, whichever comes first)
Interested in this trial?
Contact the study team directly or view the official listing
Study Information
Type: INTERVENTIONAL
Phase: NA
Status: Recruiting
Start Date: 2026-01-16
Completion: 2028-05-22
Eligibility
Age: 22 Years and older
Sex: ALL
Volunteers: false
Enrollment: 82 (ESTIMATED)
Sponsor & Investigators
Lead Sponsor: Barbara Ann Karmanos Cancer Institute
Contact Information
Study Contact:
Hadeel Assad, M.D.
1-800-527-6266
Assadh@karmanos.org
989-667-2370
Karmanos Cancer Institute at McLaren Bay Region
248-922-6650
Karmanos Cancer Institute at McLaren Clarkston
Interventions
  • Device: TheraBionic P1 — Amplitude-modulated electromagnetic fields will be self-administered and given continuously to patients in three 60-minute treatments per day, administered in the morning, middle of the day, and in the evening
Study Locations (8 sites)
Karmanos Cancer Institute at McLaren Bay Region, Bay City, Michigan 48706 United States
Karmanos Cancer Institute at McLaren Clarkston, Clarkston, Michigan 48346 United States
Karmanos Cancer Institute, Detroit, Michigan 48201 United States
Karmanos Cancer Institute at McLaren Flint, Flint, Michigan 48532 United States
Karmanos Cancer Institute at McLaren Lapeer Region, Lapeer, Michigan 48446 United States
Karmanos Cancer Institute at McLaren Macomb, Mount Clemens, Michigan 48043 United States
Karmanos Cancer Institute at McLaren Northern, Petoskey, Michigan 49770 United States
Karmanos Cancer Institute at McLaren Port Huron, Port Huron, Michigan 48060 United States
Eligibility Criteria
Inclusion Criteria: * Participant must have locally advanced/unresectable or metastatic Hormone Receptor (HR) positive, Human Epidermal growth factor receptor 2 (HER2) negative breast cancer as defined by the 2010 American Society of Clinical Oncology (ASCO) College of American Pathologists (CAP) guidelines (estrogen receptor \[ER\] and/or progesterone receptor \[PR\] \>1% and HER2 negative by immunohistochemistry \[IHC\] and/or fluorescent in situ hybridization \[FISH\]). * Participant must have received and progressed on or are intolerant to all therapies known to confer overall survival benefit, including at least one line of endocrine + CDK4/6 inhibitor therapy AND one line of cytotoxic such as chemotherapy and/or antibody drug conjugates (ADCs). * Participant must be a woman ≥ 22 years old and must be able to understand and sign an informed consent form. * Participant must have a life expectancy of at least 3 months. * Participant must have an Eastern Cooperative Oncology Group (ECOG) performance score of 0-2. * it is not known what effects this treatment has on human pregnancy or development of the embryo or fetus. Therefore, women of childbearing potential must agree to avoid becoming pregnant starting at initiation of treatment up until at least 30 days after the last TheraBionic P1 session. * Participants must meet one of the following: * Surgically sterile (hysterectomy, bilateral oophorectomy, or bilateral salpingectomy) * Post-menopausal, defined as no menses for at least 12 months prior to the screening visit without alternative medical causation. * Agree to practice true abstinence when this is in line with the preferred and usual lifestyle of the participant. Periodic abstinence methods such as calendar, ovulation, symptothermal, or post ovulation tracking are not acceptable. * Not in a sexual relationship in which they may become pregnant (i.e. same-sex relationship) * If they are of childbearing potential, agree to use at least one method of contraception. Withdrawal is not an acceptable contraceptive method. Exclusion Criteria: * Participants with known active secondary malignancy, unless, in the opinion of the investigator, it is unlikely to interfere with the safety and efficacy of the endpoints * Participants that are taking any other investigational drugs. * Participants that are pregnant or breastfeeding. If a breastfeeding participant would like to be part of this study, breastfeeding must be discontinued. * Participants with active oral mucosal inflammation, ulceration, or other pathology that could interfere with the use of TheraBionic P1 device (for example: mucositis, thrush, bleeding mucosal lesions, oral herpes, aphthous stomatitis, mouth ulcers, chancre sores, gingivostomatitis, herpangina, aphthae). * Participants receiving calcium channel blockers and any agent blocking L-type or T-type voltage gated calcium channels (for example: amlodipine, nifedipine, ethosuximide, ascorbic acid/vitamin C, etc.) unless their medical treatment is discontinued at least one day prior to treatment. Participant must agree to abstain from using calcium channel blockers for the duration of treatment on study. * Participants that do not agree to be followed according to the study protocol or have cognitive or physical inability to use the device. * Participants with a known severe (e.g., anaphylactic) allergy to nickel
Conditions Breast Reconstruction
Phase NA
Enrollment 212
Locations 1 sites
Compensation Not reported — ask the study team
Data Updated 2026-09-27
Study Details Design, interventions, and primary outcomes

About This Study

The broad aim of this study is to compare the effectiveness of paravertebral and pectoral blocks on pain and physical well-being of patients undergoing immediate implant-based breast reconstruction.

Design

Study type: Interventional Phases: Allocation: Randomized Intervention model: Parallel Primary purpose: Supportive Care Masking/blinding: None

Interventions / Regimen

  • Procedure: Paravertebral block (single injection) — Paravertebral block at preop
  • Procedure: Pectoral block — Pectoral block at preop

Primary Outcomes

  • Patient-reported physical well-being and breast symptoms (12 Months)
  • Brief Pain Inventory (BPI) Scoring (12 Months)
Interested in this trial?
Contact the study team directly or view the official listing
Study Information
Type: INTERVENTIONAL
Phase: NA
Status: Recruiting
Start Date: 2025-11-19
Completion: 2028-06
Eligibility
Age: 18 Years and older
Sex: ALL
Volunteers: false
Enrollment: 212 (ESTIMATED)
Sponsor & Investigators
Lead Sponsor: Amy Colwell
Principal Investigators:
  • Amy Colwell, M.D. (PRINCIPAL_INVESTIGATOR) - Massachusetts General Hospital
Contact Information
Study Contact:
Cathleen Huang, D.O.
617-726-2284
CHUANG24@DFCI.HARVARD.EDU
Cathleen Huang, D.O.
617-726-2284
CHUANG24@DFCI.HARVARD.EDU
Massachusetts General Hospital
Amy Colwell, M.D.
Massachusetts General Hospital
Interventions
  • Procedure: Paravertebral block (single injection) — Paravertebral block at preop
  • Procedure: Pectoral block — Pectoral block at preop
Study Locations (1 sites)
Massachusetts General Hospital, Boston, Massachusetts 02114 United States
Eligibility Criteria
Inclusion Criteria: * Adult patient 18 years or older * Scheduled for unilateral or bilateral immediate implant-based breast reconstruction * Therapeutic or prophylactic indication * Patient understands the study procedures and objectives and is willing to participate * Patient willing to and capable of providing informed consent Exclusion Criteria: * Delayed breast reconstruction * Allergy or contraindication to local anesthetics (PVB or PECS blocks) * History of radiation therapy * Planned sedation or general anesthesia protocol variation * Morbid obesity as defined as a BMI greater than 40 kg/m2 * Renal insufficiency * Chronic pain syndrome or central sensitization disorders (e.g., fibromyalgia, CRPS) * Use of implanted pain devices or neuromodulators * Pre-existing neurological deficits in the surgical field * Current chronic opioid use (daily use within the 2 weeks before surgery and duration of use greater than 4 weeks) * Use of any nerve medications in the past 6 months, including antiepileptic medications (gabapentin, carbamazepine) * History of drug or alcohol abuse or habitual alcohol intake greater than two standard drinks per day (e.g., two beers, two glasses of wine, or two mixed drinks) * Any comorbidity that results in moderate or severe functional limitation, inability to communicate with the investigators or hospital staff * History of a psychiatric disorder which would interfere with the study procedure * Incarceration * Any issue that at the discretion of the investigator would contraindicate the subject's participation * Inability to understand the procedures and objectives of the study * Inability to or unwilling to provide informed consent
Conditions Treatment-Resistant Depression
Phase NA
Enrollment 140
Locations 1 sites
Compensation Not reported — ask the study team
Data Updated 2026-09-27
Study Details Design, interventions, and primary outcomes

About This Study

Approximately one third of individuals with Major Depressive Disorder (MDD) are considered treatment-resistant, subject to severe disability and risk of suicide, and exhibit symptoms anchored in abnormalities of Research Domain Criteria (RDoC) Negative Valence Systems behavioral processes. In the present study we plan to use low-intensity focused ultrasound in 120 persons with treatment-resistant MDD to modulate deep white matter tracts connecting the thalamus and different regions of the prefrontal cortex reversibly and non-invasively, with the aim of assigning a causal, mechanistic role to large scale brain circuits in the production of those critical behavioral abnormalities. A successful study will help to attain the precise definition of neuromodulation targets for this clinical population in utter need of help.

Design

Study type: Interventional Phases: Allocation: Randomized Intervention model: Crossover Primary purpose: Basic Science Masking/blinding: Triple

Interventions / Regimen

  • Other: Low-intensity focused ultrasound — 80-second stimulus with an estimated tissue ISSPA=2.26 W/cm2, with (sham) or without (verum) interposition of Sorbothane film

Primary Outcomes

  • Post-Sonication Changes in Functional Connectivity (Pre- vs up to 30 minutes post-sonication or sham intervention.)
  • Post-Sonication Changes in Reward and Repetitive Mentation (Up to 30 minutes post-sonication vs sham intervention)
Interested in this trial?
Contact the study team directly or view the official listing
Study Information
Type: INTERVENTIONAL
Phase: NA
Status: Recruiting
Start Date: 2025-09-30
Completion: 2030-07
Eligibility
Age: 18 Years and older
Sex: ALL
Volunteers: false
Enrollment: 140 (ESTIMATED)
Sponsor & Investigators
Lead Sponsor: Laureate Institute for Brain Research, Inc.
Contact Information
Study Contact:
Salvador M Guinjoan, MD, PhD
918-502-5119
sguinjoan@laureateinstitute.org
Danielle E Clark, MA
918-701-9610
dclark@laureateinstitute.org
Salvador M Guinjoan, MD, PhD
918-502-5119
sguinjoan@laureateinstitute.org
Laureate Institute for Brain Research
Interventions
  • Other: Low-intensity focused ultrasound — 80-second stimulus with an estimated tissue ISSPA=2.26 W/cm2, with (sham) or without (verum) interposition of Sorbothane film
Study Locations (1 sites)
Laureate Institute for Brain Research, Tulsa, Oklahoma 74136 United States
Eligibility Criteria
Inclusion Criteria: 1. Persons 18-65 years old, with sex and ethnicity recruitment targets including a M:F proportion of 1:2 and White:Black:Hispanic:Native American proportion as close as possible to 8:2:2:1 to reflect the regional epidemiology of TRD (63% White American; 16% African American; 14% Hispanic of any race; 5% Native American), 2. DSM-5-TR diagnosis of MDD as confirmed by MINI structured interview followed by consultation with a board-certified psychiatrist, 3. Evidence of treatment resistance defined as continued MDD symptoms despite any of the following: 1. two or more adequate (6 week) trials of antidepressants with different mechanisms, 2. evidence-based psychotherapy, 3. augmentation agent (lithium, atypical antipsychotic, or T3), or 4. consideration of ECT or prior ECT nonresponse or intolerance, 4. at least moderate symptoms as indicated by MADRS≥20 upon screening 5. stable treatments including psychotherapy and medication for at least six weeks prior to participation. 6. Fluent English speaker, capable of written consent 7. Consent that random observations of pathology are possible (e.g., brain abnormality seen during imaging) Exclusion Criteria: 1. Clinical history of at least minor neurocognitive disorder of neurodegenerative origin, 2. PROMIS (Cognitive Function scale) score ≤40 (i.e., mean - 1SD), collected at baseline 3. clinical history of relevant structural pathology of the central nervous system, including Parkinson's disease, multiple sclerosis, and brain malignant neoplasia, 4. uncontrolled diabetes mellitus (as evidenced by a fasting glycemia ≥ 120 mg/dL or hemoglobin A1c ≥ 6.5%) or hypertension (as evidenced by two consecutive readings ≥ 140/90 mmHg) to ensure medical stability, collected at baseline 5. pregnancy or lactation, 6. Has positive test result(s) for alcohol or drugs of abuse (including methadone, opiates, cocaine, amphetamine/methamphetamine, and ecstasy), or substance use disorder including alcohol, stimulants, sedatives, and cannabis exceeding mild severity in the last 6 months, 7. active suicidal ideation (as measured by Suicide-Risk-Assessment-C-SSRS75 "Yes" answers to items 3, 4 or 5 of Suicidal Ideation-Past 1 month section, or any "Yes" answer to any of the items of Suicidal Behavior-Past 3 months section), or any suicide attempt in the last 3 months, collected at baseline 8. MRI contraindications as detected by the MRI Safety Screen, including unwillingness/unable to complete MRI scans 9. medical history indicative of moderate to severe traumatic brain injury as evidenced by history of \> 5 minutes of loss of consciousness, or of skull fractures, which in theory could distort LIFU tissue propagation, and 10. a current diagnosis of a psychotic disorder (e.g. schizophrenia, bipolar disorder), an eating disorder (e.g. anorexia or bulimia nervosa), learning disability, or a personality disorder that is considered by the investigator to interfere with the ability of the subject to adhere to the protocol (e.g., narcissistic personality disorder, borderline personality disorder). 11. Has a history of moderate or severe substance or alcohol use disorder according to DSM-5-TR 12. Use of benzodiazepines or anticonvulsants in the 7 days prior ot screening 13. Medical, psychiatric, or other conditions that restrict the patient's following abilities: to interpret the study information, to give informed consent, to adhere to the rules of the protocol, or to complete the study. 14. No reliable method of communication (i.e., no access to internet or phone connection) 15. Prescription of a medication outside of the accepted range, as determined by best clinical practices and current research 16. Unwilligness or inability to complete any of the major aspects of the study protocol 17. Non-correctable vision or hearing problems
Conditions Hypertension
Phase PHASE1
Enrollment 86
Locations 2 sites
Compensation Not reported — ask the study team
Data Updated 2026-09-27
Study Details Design, interventions, and primary outcomes

About This Study

The purpose of this study is to evaluate the safety,tolerability,pharmacokinetics and pharmacodynamics of VB19055 in the healthy Chinese population.

Design

Study type: Interventional Phases: Phase1 Allocation: Randomized Intervention model: Parallel Primary purpose: Treatment Masking/blinding: Quadruple

Interventions / Regimen

  • Drug: VB19055 — In this part, VB19055 tablets will be administered as a single or multiple oral dose.
  • Drug: VB19055 placebo — In this part, VB19055 placebo tablets will be administered as a single or multiple oral dose.

Primary Outcomes

  • Incidence and severity of treatment emergent Adverse Events as assessed by CTCAE v5.0 (Average half a month)
Interested in this trial?
Contact the study team directly or view the official listing
Study Information
Type: INTERVENTIONAL
Phase: PHASE1
Status: Recruiting
Start Date: 2025-10-05
Completion: 2026-07
Eligibility
Age: 18 Years and older
Sex: ALL
Volunteers: true
Enrollment: 86 (ESTIMATED)
Sponsor & Investigators
Lead Sponsor: Zhejiang Yangli Pharmaceutical Technology Co., Ltd.
Principal Investigators:
  • Jiguang Wang (PRINCIPAL_INVESTIGATOR) - Ruijin Hospital
Contact Information
Study Contact:
Jia Song
China 86+18503817651
songjia@vybio.com
Xiaoqi Cao
China 86+15238088632
caoxiaoqi@vybio.com
Ying Wang
China 86+0571-56007501
nancywangying@163.com
Hangzhou First People's Hospital
Interventions
  • Drug: VB19055 — In this part, VB19055 tablets will be administered as a single or multiple oral dose.
  • Drug: VB19055 placebo — In this part, VB19055 placebo tablets will be administered as a single or multiple oral dose.
Study Locations (2 sites)
Hangzhou First People's Hospital, Hangzhou, China
Ruijin Hospital Affiliated to Shanghai Jiaotong University School of Medicine, Shanghai, 200025 China
Eligibility Criteria
Inclusion Criteria: 1. Voluntarily participate in clinical trials, understand the nature of the study and any risks involved in participation, sign an informed consent form, and be willing to comply with the requirements specified in the protocol; 2. Aged between 18 and 50 years (inclusive), healthy volunteers; 3. Body mass index (BMI) between 18-26 kg/m² (inclusive), with minimum weight requirements of 50 kg (inclusive) for males and 45 kg (inclusive) for females; 4. In generally good health, as determined by the investigator based on medical history, surgical history, complete physical examination, vital signs measurements, laboratory tests, 12-lead electrocardiogram (ECG), and chest X-ray results, with no evidence of clinical disease and confirmed to be healthy; 5. For females of childbearing potential: Agree to use highly effective contraception (e.g., intrauterine device, hormonal contraceptives, or condoms) throughout the study and for 3 months after the last dose, with a negative serum pregnancy test at screening. For males: Agree to use effective contraception (specific methods detailed in Appendix 5) during the study and for 3 months after the last dose. Exclusion Criteria: 1. Known allergy to aldosterone synthase inhibitors or any components/excipients of the investigational drug; 2. The clinically significant endocrine, metabolic, cardiovascular, respiratory, gastrointestinal, liver and kidney, nervous system (including the history of seizures) or any significant history of mental illness or mental disorder, or clinically significant diseases, conditions or other evidence, which the researcher believes will pose risks to the safety of the subjects or interfere with the development, conduct or completion of the study; 3. Any known diseases or conditions that may interfere with drug absorption, distribution, metabolism or excretion (such as dysphagia or gastrointestinal diseases that affect drug absorption, or previous gastric surgery, vagotomy, enterotomy or any surgery that may interfere with gastrointestinal peristalsis, PH or absorption, etc.); 4. Vaccination with active or attenuated vaccine within 4 weeks before screening or during the trial (except influenza vaccine); 5. Drinking excessive amounts of tea, coffee and/or caffeinated beverages (more than 8 cups, 1 cup =250mL) per day, or drinking tea, coffee and/or caffeinated beverages within 48 hours before drug administration, or unable to stop drinking during the trial; Had a history of long-term consumption of a beverage or food rich in xanthine or grapefruit, or had taken any product rich in xanthine or grapefruit within 48 hours before administration; 6. Smokers or those who used nicotine products excessively (≥5 cigarettes per day on average) in the 3 months before screening or who were unable to stop using any tobacco or nicotine-based products (snus, chewing tobacco, cigars, pipes, or nicotine-replacement products) during the trial; 7. Participants who had participated in a clinical trial of another drug and had taken any investigational drug within 3 months before the first dose; 8. Use of corticosteroids within 3 months prior to the first dose; 9. Within 3 months before the first dose of blood donation or blood loss≥400 ml, blood transfusion or use of blood products, or plans to test during or within 30 days after the last drug blood donors; 10. Were heavy drinkers or regular drinkers in the 3 months before screening, which was defined as having consumed an average of 14 standard units of alcohol per week (one unit of alcohol =285mL of beer or 25mL of spirits or 125mL of wine), had a positive alcohol breath test at screening, or were unable to stop using any alcohol-containing product during the trial; 11. Drug abuse screening is positive or in the past five years has a history of substance abuse or screening before 3 months used drugs; 12. Blood pressure in the range of 90-140mmHg (systolic) or 50-90mmHg (diastolic) or pulse rate in the range of 50-100 beats/min during the screening period;Or postural hypotension (systolic blood pressure decreased ≥20mmHg or diastolic blood pressure decreased ≥ 10mmHg while standing); 13. During the screening period, any one of the infectious disease screening results of hepatitis B surface antigen (HBsAg), hepatitis C (HCV) antibody, HIV antibody and treponema pallidum antibody was positive; 14. The presence of uncontrolled active bacterial, viral, fungal, rickettsial, or parasitic infections, unless treated prior to study treatment and had returned to normal; 15. Use of any medication (including prescription drugs, over-the-counter drugs, herbal medicines, functional vitamins, supplements, etc.) within 14 days before the first dose (or within 5 half-lives of the drug used, whichever is longer) that the investigator considers may affect the evaluation of the pharmacokinetic characteristics of the study drug or interfere with the study procedures or affect the safety assessment; 16. Serum potassium level \<3.5 mmol/L or ≥5.0 mmol/L at screening and admission; 17. Subjects with aspartate aminotransferase (AST), alanine aminotransferase (ALT), or total bilirubin \>1.5 times the upper limit of normal (ULN) at screening or admission; 18. Abnormal renal function (estimated glomerular filtration rate \< 90 mL/ minute /1.73m2 using the Chronic Kidney Disease Epidemiology Collaboration \[CKD-EPI\] equation, as described in Appendix 1: CKD-EPI equation); 19. Family history of long or short QT syndrome, history of syncope or torsdes pointes, heart failure, or clinically significant/symptomatic bradycardia, and risk factors including uncontrolled hypokalemia, hypocalcemia, or hypomagnesemia.For participants in the QT/QTc study, use of antiarrhythmic drugs, inotropic drugs, beta-blockers, calcium-channel blockers, quinolones, and other drugs with a risk of prolonging the QT/QTc interval or causing torsdes pointes within 4 weeks before the first dose (see Appendix 3 for details); And prolonged QTcF interval (\> 450msec); 20. Clinically significant abnormal ECG findings at screening or admission as judged by the investigator; Strenuous physical training or excessive exercise (e.g., long-distance running, weight lifting, or any physical activity to which the participant is not accustomed) from 7 days before administration until the end of the study; 21. The investigator judged that the subject had other conditions that were not suitable for participation in this study.
Conditions Breast Cancer With Brain Metastasis, HER...
Phase PHASE2
Enrollment 140
Locations 1 sites
Compensation Not reported — ask the study team
Data Updated 2026-09-27
Study Details Design, interventions, and primary outcomes

About This Study

A phase II, open-label, multicenter, randomized controlled trial exploring the efficacy and safety of Trastuzumab Deruxtecan combined with or without Bevicizumab in HER2-low breast cancer with brain metastasis.

Design

Study type: Interventional Phases: Phase2 Allocation: Randomized Intervention model: Parallel Primary purpose: Treatment Masking/blinding: None

Interventions / Regimen

  • Drug: Bevacizumab (Bev) — Bevacizumab is a drug that targets vascular endothelial growth factor (VEGF) and inhibits tumor angiogenesis, thereby inhibiting tumor growth and spread. In the treatment of breast cancer, Bevacizumab can be used in combination with chemotherapy to improve treatment outcomes and extend patients' progression-free survival and overall survival.
  • Drug: Trastuzumab Deruxtecan (T-DXd) — Trastuzumab deruxtecan (T-DXd) is an antibody-drug conjugate (ADC) composed of an anti-HER2 monoclonal antibody (trastuzumab), a cleavable linker, and a topoisomerase I inhibitor (an exatecan derivative). It targets and binds to HER2-positive tumor cells, internalizes, and releases cytotoxic drugs to induce DNA damage and apoptosis. It also has a "bystander effect" that can kill neighboring tumor cells with low HER2 expression, enhancing anti-tumor activity. T-DXd has shown significant efficacy in HER2-positive advanced breast cancer, with key clinical trials (such as DESTINY-Breast03) confirming that its progression-free survival (PFS) and overall survival (OS) are superior to traditional second-line treatments, with a median PFS reaching 28.8 months. Additionally, for HER2-low-expressing (IHC 1+ or 2+/ISH-) metastatic breast cancer (in the DESTINY-Breast04 study), T-DXd can extend PFS and OS, becoming the first targeted therapy to alter the survival outcomes of such patients.

Primary Outcomes

  • Progression Free Survival(PFS) (12 months)
Interested in this trial?
Contact the study team directly or view the official listing
Study Information
Type: INTERVENTIONAL
Phase: PHASE2
Status: Recruiting
Start Date: 2025-10-20
Completion: 2028-09
Eligibility
Age: 18 Years and older
Sex: FEMALE
Volunteers: false
Enrollment: 140 (ESTIMATED)
Sponsor & Investigators
Lead Sponsor: Fudan University
Contact Information
Study Contact:
Zhimin Shao, Professor
08664175590 Ext. 88807
zhimingshao@yahoo.com
Guantian Lang, Doctor
08664175590 Ext. 65277
langguantian@126.com
Zhimin Shao, Professor
8664175590 Ext. 88807
zhimingshao@yahoo.com
Fudan University Shanghai Cancer Center
Interventions
  • Drug: Bevacizumab (Bev) — Bevacizumab is a drug that targets vascular endothelial growth factor (VEGF) and inhibits tumor angiogenesis, thereby inhibiting tumor growth and spread. In the treatment of breast cancer, Bevacizumab can be used in combination with chemotherapy to improve treatment outcomes and extend patients' progression-free survival and overall survival.
  • Drug: Trastuzumab Deruxtecan (T-DXd) — Trastuzumab deruxtecan (T-DXd) is an antibody-drug conjugate (ADC) composed of an anti-HER2 monoclonal antibody (trastuzumab), a cleavable linker, and a topoisomerase I inhibitor (an exatecan derivative). It targets and binds to HER2-positive tumor cells, internalizes, and releases cytotoxic drugs to induce DNA damage and apoptosis. It also has a "bystander effect" that can kill neighboring tumor cells with low HER2 expression, enhancing anti-tumor activity. T-DXd has shown significant efficacy in HER2-positive advanced breast cancer, with key clinical trials (such as DESTINY-Breast03) confirming that its progression-free survival (PFS) and overall survival (OS) are superior to traditional second-line treatments, with a median PFS reaching 28.8 months. Additionally, for HER2-low-expressing (IHC 1+ or 2+/ISH-) metastatic breast cancer (in the DESTINY-Breast04 study), T-DXd can extend PFS and OS, becoming the first targeted therapy to alter the survival outcomes of such patients.
Study Locations (1 sites)
Fudan University Shanghai Cancer Center, Shanghai, 200032 China
Eligibility Criteria
Inclusion Criteria: 1. ECOG score of 0 to 1. 2. Expected survival period greater than 12 weeks. 3. Histologically confirmed invasive HER2-low expressing breast cancer (specific definition: breast cancer patients with low expression of human epidermal growth factor receptor 2 (HER-2) as determined by pathological testing. Specifically: HER2 IHC 1+ or HER2 IHC++ with FISH/CISH negative. All specimens must be verified by the pathology department of the research participating center. 4. Tumor stage: recurrent or metastatic breast cancer; local recurrence must be confirmed by the researcher to be unable to undergo radical surgical resection. 5. Patients must have at least one lesion that has not previously received radiation therapy (measurable and/or non-measurable). 6. MRI or CT shows brain metastasis and meets one of the following conditions: i) Untreated brain parenchymal metastasis found by imaging screening; ii) Previously locally treated stable or progressive brain parenchymal metastasis and meets one of the following conditions:a) Imaging stability ≥4 weeks; b) New brain parenchymal metastasis found by MR or CT. 7. Received no more than 2 lines of chemotherapy after metastasis. 8. HR-positive patients must have previously received CDK4/6 inhibitor treatment, whether in the adjuvant treatment phase or in the recurrent metastatic phase. 9. Never used T-DXd or bevacizumab before. 10. The main organ functions are basically normal, meeting the following conditions: 11. Blood routine examination standards must comply with: HB≥90g/L (not transfused within 14 days); ANC≥1.5×10\^9/L; PLT≥75×10\^9/L; 12. Biochemical examination must comply with the following standards: TBIL≤1.5×ULN (upper limit of normal); ALT and AST≤3×ULN; if there is liver metastasis, ALT and AST≤5×ULN; serum Cr ≤1.5×ULN, endogenous creatinine clearance rate ≥30mL/min. 13. Allowed to use mannitol, hormone therapy before enrollment, but the drug treatment dose can be stable for at least one week without the need for an increase. 14. Female subjects with reproductive capacity need to use one medically recognized contraceptive method during the study treatment period and for at least 3 months after the last use of the study drug. 15. Subjects voluntarily join this study, sign an informed consent form, have good compliance, and cooperate with follow-up. Exclusion Criteria: 1. Received more than 2 lines of chemotherapy. 2. Used T-DXd or bevacizumab. 3. Meningeal metastasis. 4. Brain metastasis requiring emergency intervention treatment, or brain metastasis requiring treatment with more than 3mg/d of dexamethasone or equivalent medication. 5. Clinical significant or uncontrolled cardiac disease history, including congestive heart failure, angina, myocardial infarction within the past 6 months, or ventricular arrhythmia. 6. Ongoing adverse reactions of grade \>1 due to previous treatment. The exception is alopecia or those that the researcher believes should not be excluded. Such cases should be clearly documented in the investigator's notes. 7. Pregnant patients. 8. History of other malignancies within the past 5 years, excluding cured cervical carcinoma in situ, skin basal cell carcinoma, or skin squamous cell carcinoma. 9. Inability to swallow, chronic diarrhea, and intestinal obstruction, with multiple factors affecting drug intake and absorption. 10. Third space fluid accumulation (such as massive pleural effusion and ascites) that cannot be controlled by drainage or other methods. 11. Participated in another antitumor drug clinical trial within 4 weeks before the first administration of the study drug. 12. Long-term non-healing wounds or incompletely healed fractures. 13. Known HBV or HCV infection during the active phase or HBV DNA ≥500, or chronic phase with abnormal liver function. 14. Active primary immunodeficiency, known HIV test positive. 15. Uncontrolled infection requiring intravenous antibiotics, antiviral drugs, or antifungal drugs. 16. History of (non-infectious) ILD/pneumonia requiring steroids, currently having ILD/pneumonia, or unable to exclude suspected ILD/pneumonia on imaging during screening. 17. Pulmonary criteria: 18. Clinically significant pulmonary comorbidities, including but not limited to any underlying pulmonary disease (e.g., pulmonary embolism, severe asthma, severe chronic obstructive pulmonary disease, restrictive lung disease, pleural effusion, etc.) within 3 months of study recruitment. 19. Any autoimmune disease, connective tissue disease, or inflammatory disease (e.g., rheumatoid arthritis, Sjögren's syndrome, sarcoidosis, etc.) with recorded or suspected pulmonary involvement during screening. All detailed information about the disease should be recorded in the CRF for participants in the study. 20. Previous total pneumonectomy. 21. Allergic constitution, or known history of allergy to any component of the study regimen, or allergic to other monoclonal antibodies. 22. History of gastrointestinal bleeding within the past 6 months or a clear tendency for gastrointestinal bleeding, such as: esophageal varices at risk of bleeding, local active ulcer lesions, fecal occult blood ≥ (++) not eligible for enrollment; if fecal occult blood (+), gastroscopy is required; 23. Abdominal fistula, gastrointestinal perforation, or intra-abdominal abscess within 28 days before participating in this study; 24. Urinalysis shows urine protein ≥++ or confirmed 24-hour urine protein quantitative \>1.0g; 25. Hypertension, and blood pressure cannot be lowered to the normal range with antihypertensive drugs (systolic blood pressure \>140mmHg, diastolic blood pressure \>90mmHg). 26. Substance abuse or medical conditions that the researcher believes may interfere with the subject's participation in the clinical study or the assessment of the clinical study results.